Trastuzumab induces gastrointestinal side effects in HER2-overexpressing breast cancer patients

被引：20

作者：

Al-Dasooqi, Noor ^{[1
,2
]}

Bowen, Joanne M. ^{[1
,3
]}

Gibson, Rachel J. ^{[1
,4
]}

Sullivan, Thomas ^{[5
]}

Lees, Jude ^{[6
]}

Keefe, Dorothy M. ^{[1
,3
,7
]}

机构：

[1] Royal Adelaide Hosp, Dept Med Oncol, Adelaide, SA 5000, Australia

[2] Univ Adelaide, Dept Physiol, Adelaide, SA, Australia

[3] Univ Adelaide, Dept Med, Adelaide, SA 5001, Australia

[4] Univ Adelaide, Discipline Anat Sci, Adelaide, SA, Australia

[5] Univ Adelaide, Discipline Publ Hlth, Adelaide, SA, Australia

[6] Royal Adelaide Hosp, RAH Canc Ctr, Adelaide, SA 5000, Australia

[7] Canc Council S Australia, Eastwood, SA, Australia

来源：

INVESTIGATIONAL NEW DRUGS | 2009年 / 27卷 / 02期

关键词：

HER2-overexpressing breast cancer; Targeted therapy; Trastuzumab; Gastrointestinal tract; Toxicity; ADJUVANT CHEMOTHERAPY; MONOCLONAL-ANTIBODY; MUCOSAL INJURY; EXPRESSION; ERBB2; THERAPY; COMPLEX; EMESIS; LIGAND;

D O I：

10.1007/s10637-008-9152-1

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Purpose: To characterise the gastrointestinal toxicities associated with Trastuzumab administration in HER2-overexpressing breast cancer patients. Methods: All patients (n = 46) who received Trastuzumab as a single agent or in conjunction with conventional anti-cancer treatment within the Royal Adelaide Hospital Cancer Centre from 2002-2007 were included in this study. A retrospective analysis of case-notes was conducted to investigate the toxicities associated with Trastuzumab. Results: Trastuzumab as a single agent induced toxicities following 22% of administrations. Gastrointestinal toxicities were observed following 12% of administrations and included nausea and vomiting, diarrhoea, abdominal pain and bloating. However, other prominent toxicities that were not related to the gastrointestinal tract were also observed including fatigue and lung symptoms (10.4%). Elderly patients (a parts per thousand yen60 years) and those with metastatic disease experienced the highest frequency of toxicity. Conclusion: Trastuzumab induces a range of gastrointestinal toxicities in HER2-overexpressing breast cancer patients. These toxicities are separate to those caused by concurrent chemotherapy and/or radiotherapy.

引用

页码：173 / 178

页数：6

共 33 条

[1] Evaluation of the elderly with cancer [J].

Aapro, M ;

Extermann, M ;

Repetto, L .

ANNALS OF ONCOLOGY, 2000, 11 :223-229

[2] Chemotherapy-induced emesis in elderly cancer patients:: The role of 5-HT3-receptor antagonists in the first 24 hours [J].

Aapro, M ;

Johnson, J .

GERONTOLOGY, 2005, 51 (05) :287-296

[3] The ErbB2 signaling network as a target for breast cancer therapy [J].

Badache, Ali ;

Goncalves, Anthony .

JOURNAL OF MAMMARY GLAND BIOLOGY AND NEOPLASIA, 2006, 11 (01) :13-25

[4] Mechanism of action of trastuzumab and scientific update [J].

Baselga, J ;

Albanell, J ;

Molina, MA ;

Arribas, J .

SEMINARS IN ONCOLOGY, 2001, 28 (05) :4-11

[5] Clinical trials of Herceptin® (trastuzumab) [J].

Baselga, J .

EUROPEAN JOURNAL OF CANCER, 2001, 37 :S18-S24

[6] Cell signaling through membrane mucins [J].

Carraway, KL ;

Ramsauer, VP ;

Haq, B ;

Carraway, CAC .

BIOESSAYS, 2003, 25 (01) :66-71

[7] Muc4/sialomucin complex, the intramembrane ErbB2 ligand, in cancer and epithelia: To protect and to survive [J].

Carraway, KL ;

Perez, A ;

Idris, N ;

Jepson, S ;

Arango, M ;

Komatsu, M ;

Haq, B ;

Price-Schiavi, SA ;

Zhang, J ;

Carraway, CAC .

PROGRESS IN NUCLEIC ACID RESEARCH AND MOLECULAR BIOLOGY, VOL 71, 2002, 71 :149-185

[8] Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease [J].

Cobleigh, MA ;

Vogel, CL ;

Tripathy, D ;

Robert, NJ ;

Scholl, S ;

Fehrenbacher, L ;

Wolter, JM ;

Paton, V ;

Shak, S ;

Lieberman, G ;

Slamon, DJ .

JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (09) :2639-2648

[9] Colonic epithelial expression of ErbB2 is required for postnatal maintenance of the enteric nervous system [J].

Crone, SA ;

Negro, A ;

Trumpp, A ;

Giovannini, M ;

Lee, KF .

NEURON, 2003, 37 (01) :29-40

[10] Pooled analysis of diarrhea events in patients with cancer treated with lapatinib [J].

Crown, John P. ;

Burris, Harold A., III ;

Boyle, Fran ;

Jones, Suzanne ;

Koehler, Maria ;

Newstat, Beth O. ;

Parikh, Roma ;

Oliva, Cristina ;

Preston, Alaknanda ;

Byrne, Julie ;

Chan, Steve .

BREAST CANCER RESEARCH AND TREATMENT, 2008, 112 (02) :317-325

← 1 2 3 4 →